Arkolith/Insider Trading/VYGR/Form 4

Carter Todd Alfred

Chief Scientific OfficerVoyager Therapeutics, Inc. (VYGR) · full profile →Form 4 · filed Feb 24, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$14K
Net Open-Market Flow
-$14K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 21, 2025Grant(A)46K—$0124K
Feb 20, 2025Sell(S)3K$4.26$14K78K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 21, 2025Grant(A)92K—$092K

Transaction Codes

A
Grant / award
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-25-016522) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML